09th November 2020
PerkinElmer, Inc. (NYSE: PKI) announced today that EUROIMMUN, a PerkinElmer company, has launched the Anti-SARS-CoV-2 QuantiVac ELISA (IgG) to quantify IgG antibodies against the SARS-CoV-2 S1 antigen. This quantitative test kit applies a recombinant S1 subunit of the SARS-CoV-2 spike protein, enabling detection of IgG antibodies. Antibodies of class IgG against S1 have been the focus of vaccine development programs as well as discussions about possible immunity in previously infected individuals.
15th September 2020
The U.S. Food and Drug Administration published comparative performance data (Limit of Detection, LoD) for more than 55 authorized SARS-CoV-2 molecular diagnostic tests which have been tested against a standardized sample panel provided by the FDA. We are happy to announce that the EURORealTime SARS-CoV-2 was under the top 5 ranking assays with the lowest LoDs reported, as of today. The EURORealTime SARS-CoV-2 LoD is comparable to Roche cobas SARS-CoV-2 or Quest SARS-CoV-2 rRT-PCR. Please find the complete SARS-CoV-2 reference panel comparative data on the FDA website.
08th June 2020
Subsequent to the EUROIMMUN-Anti-SARS-CoV-2 ELISA (IgG), the EURORealTime SARS-CoV-2 for direct pathogen detection has now also been approved for use in authorised laboratories by the U.S. American Food and Drugs Administration (FDA) within the framework of an Emergency Use Authorization (EUA).
12th May 2020
EUROIMMUN UK, a subsidiary of EUROIMMUN AG, is based in London and has supported Public Health England (PHE) in establishing a serology assay for use in the National Testing Strategy since March with tens of thousands of tests delivered. The EUROIMMUN tests are being used in a serosurveillance study, the results of which will inform the UK Government’s strategy to combat the pandemic.
06th May 2020
Dear EUROIMMUN customer,
Yesterday, ourAnti-SARS-CoV-2 ELISA (IgG) was approved by the US-American Food and Drug Administration (FDA) by an emergency use authorization(EUA). The results of a new independent validation effort by the U.S. Government provided the scientific evidence used to support the authorization. We are delighted that the excellent performance and reliability of our test system was therewith also officially acknowledged in the US.
05th May 2020
WALTHAM, Mass.--(BUSINESS WIRE)--May 5, 2020-- PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that the U.S. Food and Drug Administration (FDA) has provided Emergency Use Authorization (EUA) for EUROIMMUN’s (a PerkinElmer company) Anti-SARS-CoV-2 ELISA (IgG) serology test. Clinical laboratories certified to perform high complexity tests under Clinical Laboratory Improvement Amendments (CLIA) can immediately begin using this ELISA for the detection of antibodies of the immunoglobulin class G.